Artificial Blood Market:
Artificial Blood acts as a substitute for red blood cell which is designed to carry out the transporting of oxygen and carbon dioxide throughout the body. Artificial Blood comprises of Hemoglobin-Based Oxygen Carriers (HBOCs) and Perfluorocarbon Emulsions (PFCEs). Perfluorocarbon Emulsions (PFCEs) are chemically inert and are very much able to dissolve and absorb oxygen in the lungs and then transport it all over the body. With new research, scientists are creating artificial blood which can be produced on an industrial scale.
Artificial Blood is produced in many different ways depending on the type of Artificial Blood such as chemical isolation, synthetic production, or recombinant biochemical technology. It has still not been marketed but once in the field, the market will have promising potential. Red Blood Cells are responsible for the transportation of oxygen and carbon dioxide throughout the body. Artificial Blood products can only replace the function of red blood cells. The requirement of blood replacements is greater in case of major injury.
Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/4590218-global-artificial-blood-market-professional-survey-report-2019
Artificial Blood is needed in case of surgery and for intra-operative blood loss. Blood is essential for survival. It plays a vital role throughout the body. Blood prevents and fights with the illnesses and infections. Blood can form the clots, which prevents it from fatal blood loss. The growing rate of cancer and other medical conditions will increase the sales of Artificial Blood. With ongoing research to develop a better substitute for blood, the market of Artificial Blood will witness a huge growth.
Market Key Player:
Dextro-Sang Corporation, BioPure Corporation, Sangart, Northfield Laboratories, Baxter International, Dentritech, FluorO2 Therapeutics, Nuvox Pharma, Alpha Therapeutic Corporation, HemoBioTech
By type, the global Artificial Blood market in the section – Human Blood, Synthetic Blood, and Animal Blood. By application, the global Artificial Blood market in the section – Hemoglobin-Based Oxygen Carriers (HBOCs) and Perfluorocarbon Emulsions (PFCEs). Perfluorocarbon Emulsions (PFCEs) have been found well tolerated in humans. It is given during surgery to increase oxygen delivery during surgery and also used in many other medical purposes. Hemoglobin-Based Oxygen Carriers are the synthetic oxygen carriers that are chemically modified human or bovine hemoglobin and they can carry oxygen. It is used as an alternative. HBOCs and PFC’s have a bright future in the wide range of clinical scenarios and diagnostic or therapeutic concepts.
Europe and North America’s Artificial Blood market achieve growth with the development of technologically advanced Artificial Blood for blood transfusion. With the growing need for blood transfusion during surgery in case of injury, cancer or any other medical conditions, the demand for Artificial Blood will rise at a rapid pace. South America’s Artificial Blood market achieves growth due to the growing demand for Artificial Blood. The intraoperative blood loss is a major reason for the requirement of blood. Asia-Pacific (APAC) Artificial Blood market to achieve growth due to the reduction in blood donation. The requirement of blood is more in cases of transfusion-transmitted diseases. By providing a better quality of blood the market of Artificial Blood will grow at a fast pace.
October 22, 2019. The latest study on 3D-printed fully functional blood vessels and implanting them into living hosts. With the use of bioink containing human smooth muscle cells and endothelial cells from an umbilical vein, the blood vessels were printed. They resemble the natural blood vessels with dual-layer architecture and outperform existing engineered tissues.
For further information on this report, visit – https://www.wiseguyreports.com/reports/4590218-global-artificial-blood-market-professional-survey-report-2019
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349